Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-12-26
Target enrollment:
Participant gender:
Summary
This study aims to determine the effectiveness of prophylactic antibiotic use for TACE and
occurrence of postoperative liver abscess.
There would be two comparison groups. Current standard of care treatment at PKLI&RC (as per
local guidelines) would be given to all patients receiving TACE for the intervention group or
'antibiotic group' (i.e., Inj. Ceftriaxone 1g, intravenous × stat). While no antibiotic would
be given to the 'no antibiotic group'.